Goldman / Vasavada Female Urology

A Practical Clinical Guide
1. Auflage 2008
ISBN: 978-1-59745-368-4
Verlag: Humana Press
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 434 Seiten

Reihe: Current Clinical Urology

This comprehensive and innovative volume offers a hands-on reference for the management of challenging disorders of the female lower urinary tract. The volume features scenario presentations in which a patient presentation is described and followed by two experts in the field reviewing work-up and management of the problem. Novel techniques for the treatment of voiding dysfunction are provided.

Autoren/Hrsg.

Goldman, Howard B.

Vasavada, Sandip P.

Inhaltsverzeichnis

1;Preface;7
2;Contents;8
3;Contributors;11
4;I EVALUATION;23
4.1;Anatomy of Pelvic Support;24
4.1.1;CONTENTS;24
4.1.2;INTRODUCTION;24
4.1.3;BONY PELVIS;24
4.1.4;MUSCULATURE AND FASCIAE OF THE PELVIS;26
4.1.5;PELVIC CIRCULATION;28
4.1.6;FEMALE PELVIC VISCERA Lower Urinary Tract;31
4.1.7;Genital Structures;33
4.1.8;PERINEUM;35
4.1.9;CONCLUSION;38
4.1.10;REFERENCES;38
4.2;Neurophysiological Control of Bladder Function;40
4.2.1;CONTENTS;40
4.2.2;INTRODUCTION;40
4.2.3;HIGHER LEVEL CENTRAL NERVOUS SYSTEM CONTROL OF MICTURITION AND STORAGE;47
4.2.4;CONCLUSION;51
4.2.5;REFERENCES;51
4.3;Office Evaluation of Urinary Incontinence;55
4.3.1;CONTENTS;55
4.3.2;INTRODUCTION;55
4.3.3;HISTORY;55
4.3.4;FLUID INTAKE/VOIDING DIARY;56
4.3.5;PHYSICAL EXAMINATION;56
4.3.6;LABORATORY TESTS;57
4.3.7;MULTICHANNEL URODYNAMICS;57
4.3.8;REFERENCES;59
4.4;Urodynamic Evaluation of Female Stress Urinary Incontinence;60
4.4.1;CONTENTS;60
4.4.2;INTRODUCTION;60
4.4.3;LEAK-POINT PRESSURES;60
4.4.4;URETHRAL PRESSURE PROFILOMETRY;64
4.4.5;URETHRAL RETRORESISTANCE PRESSURE;67
4.4.6;ROLE OF URODYNAMIC TESTING IN THE ASSESSMENT OF FEMALE SUI;67
4.4.7;REFERENCES;68
4.5;Urodynamic Assessment of Overactive Bladder;69
4.5.1;CONTENTS;69
4.5.2;INTRODUCTION;69
4.5.3;WHO REQUIRES URODYNAMICS?;70
4.5.4;KEY COMPONENTS IN URODYNAMIC TESTING OF OVERACTIVE BLADDER;71
4.5.5;FINDINGS IN NONNEUROGENIC OVERACTIVE BLADDER;72
4.5.6;FINDINGS IN NEUROGENIC OAB;75
4.5.7;CONCLUSION;76
4.5.8;REFERENCES;78
5;II TREATMENT;79
5.1;Conservative Therapy for Incontinence;80
5.1.1;CONTENTS;80
5.1.2;INTRODUCTION;80
5.1.3;LIFESTYLE CHANGES/BEHAVIOR MODIFICATION;80
5.1.4;TOILETING PROGRAMS;84
5.1.5;PELVIC FLOOR MUSCLE REHABILITATION OR TRAINING;86
5.1.6;CONCLUSION;92
5.1.7;REFERENCES;92
5.1.8;APPENDIX;94
6;II PART A: STRESS URINARY INCONTINENCE;97
6.1;Pharmacological Therapy for Stress Urinary Incontinence;98
6.1.1;CONTENTS;98
6.1.2;ANATOMIC AND FUNCTIONAL INFLUENCES ON CONTINENCE;99
6.1.3;HORMONE REPLACEMENT THERAPY;101
6.1.4;IMIPRAMINE;103
6.1.5;ADRENERGIC AGONISTS;104
6.1.6;ADRENOCEPTOR;105
6.1.7;AGONISTS AND ANTAGONISTS;105
6.1.8;SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS;105
6.1.9;CONCLUSION;108
6.1.10;REFERENCES;108
6.2;Urethral Injectables for Stress Urinary Incontinence;111
6.2.1;CONTENTS;111
6.2.2;HISTORICAL PERSPECTIVE;111
6.2.3;PATIENT SELECTION;112
6.2.4;SURGICAL TECHNIQUE;114
6.2.5;RESULTS;116
6.2.6;COMPLICATIONS;117
6.2.7;OTHER FDA-APPROVED INJECTABLE AGENTS Carbon- Coated Beads ( Durasphere);118
6.2.8;CONCLUSION;121
6.2.9;ACKNOWLEDGMENT;121
6.2.10;REFERENCES;121
6.3;Midurethral Slings;124
6.3.1;CONTENTS;124
6.3.2;INTRODUCTION;124
6.3.3;HISTORY AND BACKGROUND;124
6.3.4;PATIENT SELECTION;127
6.3.5;ANESTHETIC REQUIREMENTS;128
6.3.6;TECHNIQUES;128
6.3.7;MATERIALS;130
6.3.8;OUTCOMES;131
6.3.9;COMPLICATIONS;134
6.3.10;SUMMARY;139
6.3.11;REFERENCES;139
6.4;Bladder Neck Slings for Stress Urinary Incontinence;144
6.4.1;CONTENTS;144
6.4.2;INTRODUCTION;144
6.4.3;HISTORY;144
6.4.4;PATIENT SELECTION;145
6.4.5;SURGICAL TECHNIQUE AND VARIATIONS;146
6.4.6;MATERIAL, EQUIPMENT, AND TECHNICAL VARIATIONS Sling Material Selection;151
6.4.7;REFERENCES;166
6.5;Complications of Sling Surgery;172
6.5.1;CONTENTS;172
6.5.2;INTRODUCTION;172
6.5.3;INTRAOPERATIVE COMPLICATIONS Bleeding/ Hematoma Formation;173
6.5.4;POSTOPERATIVE COMPLICATIONS Postoperative Voiding Dysfunction;175
6.5.5;CONCLUSION;182
6.5.6;REFERENCES;183
7;II PART B: OVERACTIVE BLADDER;187
7.1;Pharmacological Therapy for Overactive Bladder;188
7.1.1;CONTENTS;188
7.1.2;INTRODUCTION;188
7.1.3;UROSELECTIVITY;189
7.1.4;SPECIFIC AGENTS Relatively Pure Antimuscarinic Agents;190
7.1.5;CONCLUSION;206
7.1.6;REFERENCES;206
7.2;Intravesical Treatments for Overactive Bladder;211
7.2.1;CONTENTS;211
7.2.2;ANATOMY AND FUNCTION OF THE UROEPITHELIUM;212
7.2.3;EFFERENT INNERVATION OF THE URINARY BLADDER;212
7.2.4;INTRAVESICAL OXYBUTYNIN;212
7.2.5;AFFERENT INNERVATION OF THE URINARY BLADDER:;213
7.2.6;VANILLOID PHARMACOLOGY;213
7.2.7;CLINICAL RESULTS OF INTRAVESICAL CAPSAICIN Hypersensitivity Disorders;216
7.2.8;CLINICAL RESULTS OF INTRAVESICAL RESINIFERATOXIN Interstitial Cystitis;218
7.2.9;TECHNIQUE OF INTRAVESICAL CAPSAICIN AND RESINIFERATOXIN ADMINISTRATION;219
7.2.10;CONCLUSION;219
7.2.11;REFERENCES;220
7.3;Urological Applications of Botulinum Toxin;223
7.3.1;CONTENTS;223
7.3.2;INTRODUCTION;223
7.3.3;APPLICATIONS IN UROLOGY;224
7.3.4;INJECTION TECHNIQUES;227
7.3.5;ADVERSE EVENTS AND CONTRAINDICATIONS;228
7.3.6;CONCLUSION;229
7.3.7;REFERENCES;229
7.4;Nonsacral Neuromodulation;231
7.4.1;CONTENTS;231
7.4.2;INTRODUCTION;231
7.4.3;TIBIAL NERVE STIMULATION;231
7.4.4;ANOGENITAL ELECTRICAL STIMULATION;233
7.4.5;PUDENDAL NERVE STIMULATION;234
7.4.6;CONCLUSION;244
7.4.7;REFERENCES;244
7.5;Sacral Neuromodulation for the Treatment of Overactive Bladder;246
7.5.1;CONTENTS;246
7.5.2;INTRODUCTION;246
7.5.3;CASE 1;247
7.5.4;CASE 2;247
7.5.5;HISTORY;248
7.5.6;MECHANISM OF ACTION;248
7.5.7;INDICATIONS;249
7.5.8;TEST PROCEDURE;249
7.5.9;IMPLANTABLE PULSE GENERATOR IMPLANTATION PROCEDURE;252
7.5.10;RESULTS;252
7.5.11;COMPLICATIONS;255
7.5.12;CASE STUDIES;256
7.5.13;DISCUSSION;256
7.5.14;REFERENCES;257
7.6;Augmentation Cystoplasty;259
7.6.1;CONTENTS;259
7.6.2;INTRODUCTION;259
7.6.3;INDICATIONS AND CONTRAINDICATIONS;259
7.6.4;ALTERNATIVES TO AUGMENTATION;260
7.6.5;SURGICAL TECHNIQUE OF BLADDER AUGMENTATION;260
7.6.6;RESULTS AND COMPLICATIONS;264
7.6.7;CONCLUSION;266
7.6.8;REFERENCES;266
7.7;Mixed Incontinence;268
7.7.1;CONTENTS;268
7.7.2;INTRODUCTION;268
7.7.3;DEFINITIONS AND APPROACH;268
7.7.4;EXPECTATIONS FOR RESULTS;269
7.7.5;CONCLUSION: WHAT WE DO;270
7.7.6;REFERENCES;271
8;II PART C: PROLAPSE;272
8.1;Evaluation and Management of Anterior Vaginal Wall Prolapse;273
8.1.1;CONTENTS;273
8.1.2;INTRODUCTION;273
8.1.3;EVALUATION History;274
8.1.4;SURGICAL TECHNIQUES;275
8.1.5;OUTCOMES Anterior Colporrhaphy;281
8.1.6;COMPLICATIONS;283
8.1.7;REFERENCES;284
8.2;Treatment of Vaginal Wall Prolapse;286
8.2.1;CONTENTS;286
8.2.2;INTRODUCTION;286
8.2.3;ANATOMY;287
8.2.4;SYMPTOMS;288
8.2.5;DIAGNOSIS History;288
8.2.6;INDICATIONS FOR SURGERY;291
8.2.7;SURGICAL REPAIR OF RECTOCELE;292
8.2.8;CONCLUSION;299
8.2.9;REFERENCES;299
8.3;Diagnosis and Management of Apical Prolapse;302
8.3.1;CONTENTS;302
8.3.2;INTRODUCTION;302
8.3.3;PREOPERATIVE EVALUATION;302
8.3.4;MANAGEMENT OF APICAL PROLAPSE Observation;304
8.3.5;CONCLUSION;310
8.3.6;REFERENCES;310
8.4;Evaluation and Management of Vesicovaginal Fistulas;313
8.4.1;CONTENTS;313
8.4.2;INTRODUCTION;313
8.4.3;ETIOLOGY;314
8.4.4;PREVENTION;314
8.4.5;DIAGNOSIS;314
8.4.6;CONSERVATIVE MANAGEMENT;315
8.4.7;OPERATIVE MANAGEMENT;316
8.4.8;COMPLEX FISTULAS;323
8.4.9;TISSUE INTERPOSITION;323
8.4.10;INTRAOPERATIVE COMPLICATIONS;327
8.4.11;POSTOPERATIVE MANAGEMENT (TRANSVAGINAL REPAIR);328
8.4.12;OUTCOMES;328
8.4.13;POSTOPERATIVE COMPLICATIONS;329
8.4.14;CONCLUSION;329
8.4.15;REFERENCES;329
8.5;Female Urethral Diverticula;331
8.5.1;CONTENTS;331
8.5.2;INTRODUCTION;331
8.5.3;ETIOLOGY;331
8.5.4;CLASSIFICATION;332
8.5.5;INCIDENCE;333
8.5.6;PRESENTATION AND EVALUATION;333
8.5.7;TREATMENT;336
8.5.8;PATHOLOGY;338
8.5.9;CONCLUSION;339
8.5.10;CASE 1;339
8.5.11;CASE 2;339
8.5.12;CASE 3;341
8.5.13;REFERENCES;343
9;III CASE STUDIES;345
9.1;Recurrent Stress Urinary Incontinence;346
9.1.1;COMMENTARY BY JERRY BLAIVAS,;346
9.1.2;SOURCES;347
9.1.3;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;347
9.2;Recurrent Urinary Tract Infections and Pelvic Organ Prolapse;348
9.2.1;COMMENTARY BY JENNIFER TAKACS, AND PHILIPPE ZIMMERN,;348
9.2.2;REFERENCES;351
9.2.3;EDITORÌS COMMENTS BY SANDIP P. VASAVADA,;352
9.3;Mixed Incontinence;353
9.3.1;COMMENTARY BY WACHIRA KOCHAKARN,;353
9.3.2;REFERENCES;355
9.3.3;COMMENTARY BY GARY E. LEACH,;355
9.3.4;Summary;356
9.3.5;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;356
9.4;Urinary Tract Infections and Pelvic Pain;358
9.4.1;COMMENTARY BY SUZETTE E. SUTHERLAND, Step 1: Physical Exam and Labs;358
9.4.2;REFERENCES;360
9.4.3;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;360
9.4.4;COMMENTARY BY E. JAMES WRIGHT,;361
9.5;Multiple Sclerosis and Voiding Dysfunction;361
9.5.1;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;363
9.6;De novo Overactive Bladder Symptoms After a Sling;365
9.6.1;COMMENTARY BY VICTOR W. NITTI,;365
9.6.2;REFERENCES;367
9.6.3;COMMENTARY BY CARL G. KLUTKE, AND TRAVIS L. BULLOCK,;367
9.6.4;REFERENCES;369
9.6.5;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;370
9.7;Recurrent Pelvic Organ Prolapse;371
9.7.1;COMMENTARY BY CHRISTOPHER C. ROTH, AND J. CHRISTIAN WINTERS,;371
9.7.2;REFERENCES;373
9.7.3;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;373
9.8;Recalcitrant Urinary Frequency and Urgency;374
9.8.1;COMMENTARY BY MICHAEL CHANCELLOR,;374
9.8.2;COMMENTARY BY GAMAL M. GHONIEM,;375
9.8.3;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;376
9.9;Difficulty Voiding and Overactive Bladder Symptoms;377
9.9.1;COMMENTARY BY MICHAEL J. KENNELLY,;377
9.9.2;REFERENCE;379
9.9.3;COMMENTARY BY DEBORAH LIGHTNER,;380
9.9.4;REFERENCES;381
9.9.5;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;382
9.10;Post-Hysterectomy Incontinence;383
9.10.1;COMMENTARY BY COURTENAY K. MOORE,;383
9.10.2;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;384
9.11;Severe Incontinence After Multiple Prior Procedures;385
9.11.1;COMMENTARY BY ROGER DMOCHOWSKI,;385
9.11.2;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;387
9.12;Urinary Frequency and Pelvic Pain;389
9.12.1;COMMENTARY BY E. ANN GORMLEY,;389
9.12.2;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;391
9.12.3;EDITOR’S NOTE;391
9.12.4;COMMENTARY BY JEFFREY P. WEISS,;391
9.12.5;REFERENCES;392
9.12.6;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;393
9.13;Pelvic Organ Prolapse;394
9.13.1;COMMENTARY BY SHLOMO RAZ, AND MATTHEW P. RUTMAN,;394
9.13.2;COMMENTARY BY KATHLEEN C. KOBASHI, History;396
9.13.3;REFERENCES;399
9.13.4;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;399
9.13.5;COMMENTARY BY RAYMOND RACKLEY,;401
9.14;Recurrent Pelvic Organ Prolapse After Colpocleisis;401
9.14.1;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;402
9.15;Stress Incontinence and Straining to Void;403
9.15.1;COMMENTARY BY STEVEN SIEGEL,;403
9.15.2;REFERENCES;405
9.15.3;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;405
9.16;Male With Post-Prostatectomy Incontinence;406
9.16.1;COMMENTARY BY CRAIG V. COMITER,;406
9.16.2;COMMENTARY BY FRED E. GOVIER,;408
9.16.3;REFERENCES;410
9.16.4;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;410
9.17;Mixed Incontinence in an Elderly Woman;411
9.17.1;COMMENTARY BY TOMAS L. GRIEBLING,;411
9.17.2;REFERENCES;414
9.17.3;EDITOR’S COMMENTS BY HOWARD B. GOLDMAN,;414
9.18;Male With Post-Prostatectomy Incontinence;415
9.18.1;COMMENTARY BY AJAY SINGLA,;415
9.18.2;REFERENCE;416
9.18.3;EDITOR’S COMMENTS BY SANDIP P. VASAVADA,;416
10;Index;417